XENON PHARMACEUTICALS INC. (XENE) Overview
- 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -1.11; Beat / miss (m).
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -1.17; Beat / miss (m).
- 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -1.15; Beat / miss (m).
- 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -1.07; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $39.19
- Previous close
- $37.25
- Change
- $1.94
- Change (%)
- 5.21%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- XENE
- -16.89%
- S&P 500
- (m)
1 year
- XENE
- -4.63%
- S&P 500
- (m)
3 years
- XENE
- +9.05%
- S&P 500
- (m)
5 years
- XENE
- +150.67%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual -1.11
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | -1.11 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | -1.17 | (m) | (m) |
| 1 Jul 2025 | 30 Sept 2025 | (m) | -1.15 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | -1.07 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | -0.83 | (m) | (m) |
31 Dec 2025 ○ Estimate (m) ● Actual -4.36
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2025 | 31 Dec 2025 | (m) | -4.36 | (m) | (m) |
| 1 Jan 2024 | 31 Dec 2024 | (m) | -3.01 | (m) | (m) |
| 1 Jan 2023 | 31 Dec 2023 | (m) | -2.73 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | -2.06 | (m) | (m) |
| 1 Jan 2021 | 31 Dec 2021 | (m) | -1.77 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
31 Dec 2017 ■ Revenue 0.02M ■ Earnings -8.06M — Profit margin -50406.25%
31 Dec 2017 ■ Revenue 0.31M ■ Earnings -30.70M — Profit margin -9872.67%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $39.19 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning XENE
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 31 Dec 2017.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-30.70M
- Operating margin · 12 months
- -10474.28%
- Free cash flow margin · 12 months
- -9337.94%
- Profit margin
- -9872.67%
- Return on assets · 12 month
- -54.05%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- 370.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 2.31M
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -4.71%*
- Total return · month
- -37.91%*
- Total return · quarter
- -38.05%*
- Total return · half year
- -31.63%*
- Total return · year to date
- -16.89%*
- Total return · 1 year
- -4.63%*
- Total return · 3 years
- 9.05%*
- Total return · 5 years
- 150.67%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- R&D / revenue · 12 months
- 8222.83%
- Revenue · 12 month
- $311.00K
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Operating cash flow · 12 months
- $-28.73M
- Free cash flow · 12 months (USD)
- $-29.04M
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- 18.93%*
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
XENON PHARMACEUTICALS INC. Overview
View more →(m)
(m)
- SEC CIK
- 1582313
- Industry (SIC)
- 2834 Pharmaceutical Preparations
- Country of operation
- British Columbia, Canada
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada, British Columbia, Canada
- Fiscal year end
- 1231
- Phone
- (604) 484-3300
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |